Inactive

Beta.sam.gov posting Document Type: Combined Synopsis/Solicitation Solicitation Number: RFQ-NIAID-2045775 Description: Biosensors This notice is a combined synopsis/solicitation for commercial items u... Beta.sam.gov posting Document Type: Combined Synopsis/Solicitation Solicitation Number: RFQ-NIAID-2045775 Description: Biosensors This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2045775 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-01, Effective 10/01/2020. The North American Industry Classification System (NAICS) code for this procurement is 334516, analytical laboratory instruments manufacuring, with a small business size standard of 1000 employees. This requirement is NOT set-aside for small business. Background: The Vaccine Research Center (VRC) at the National Institutes of Health (NIH) was established to facilitate research in vaccine development. The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. The mission of the Vaccine Research Center (VRC) is to conduct research that facilitates the development of effective vaccines for human disease. The Vaccine Research Center is developing vaccines for Cov2, HIV-1 and other pathogens. Production of various wild type and mutant viral proteins and anti-viral antibodies is critical in vaccine development. Making different mutations of viral proteins and expression antibodies against such proteins is critical for vaccine development. Description and purpose of the Requirement: The Vaccine Research Center (VRC) is interested in procuring Anti-human IgG Fc Capture Biosensors (Catalog # 18-5064) and Streptavidin (SA) Biosensors(Catalog # 18-5021) and Ni-NTA (NTA) Biosensors (Catalog # 18-5103) that will be used for antigenicity analysis. The biosensors will be used to detect the titers of mouse antibodies expressed by mouse B cells in 96- well culture plates. The Octet Molecular instrument is already installed at VRC. This purchase is for the biosensors that are required to run the Octect instrument. It is very critical that the same biosensors be used to preserve continuity in experiments. No alternative biosensors are acceptable. Quantity Catalog # Description 1 18-5064 Anti-human IgG Fc Capture Biosensors - Twenty trays of 96 biosensors - (4 each) 1 18-5021 Streptavidin (SA) Biosensors - Twenty trays of 96 biosensors (2 each) 1 18-5103 Ni-NTA (NTA) Biosensors - Twenty trays of 96 biosensors - (2 each) ALL OFFERORS MUST ALSO COMPLETE AND SIGN THE ATTACHED CERTIFICATION (VENDOR CERTIFICATION) Place of Performance: 40 Convent Drive Bethesda, MD 20892 Delivery Date 30 days ARO *Please include your DUNS number on quote *Include response to FAR 52.204-26 and 52.204-24 and return with quote Submission shall be received not later than 9:00 a.m. EST, November 6, 2020. The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following; price, capability to meet the requirements, delivery and the best value to the government. The following FAR provisions apply to this acquisition: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Dec 2019) FAR 52.212-1 Instructions to Offerors Commercial Items (Jun 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Aug 2020) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 - Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Oct 2020) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or email. Offers may be mailed, e-mailed to Ms. Lorena Waller, (E-Mail/ Wallerlor@niaid.nih.gov 240-669-5099). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (June 2020) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Lorena Waller @ Wallerlor@niaid.nih.gov.